T. Decker

发表

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

Shu Ichihara, Sunil Badve, Ian O Ellis, 2011, Modern Pathology.

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

J. Hasenauer, A. Walch, F. Lordick, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flache epitheliale Atypie

T. Decker, D. Hungermann, W. Böcker, 2009, Der Pathologe.

Detection Rates of Ductal Carcinoma in Situ with Biennial Digital Mammography Screening: Radiologic Findings Support Pathologic Model of Tumor Progression.

H. Hense, W. Heindel, J. Wellmann, 2017, Radiology.

Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry.

P. Sorensen, Meenakshi Singh, K. Schaefer, 2003, Human Pathology.

Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management

I. Ellis, P. Tan, S. Fox, 2016, Histopathology.

First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

E. Morris, C. Comstock, T. Decker, 2016, Breast Cancer Research and Treatment.

Quality indicators in breast cancer care.

L Biganzoli, U Bick, M P Mano, 2010, European journal of cancer.

Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group.

Roberto Orecchia, Peter Regitnig, Fiona J Gilbert, 2010, European journal of cancer.

Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2‐negative, Hormone Receptor‐positive Early Breast Cancer

P. Fasching, T. Fehm, A. Schneeweiss, 2017, Clinical breast cancer.

Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

W. Scheithauer, V. Heinemann, T. Decker, 2014 .

Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study

J. Peterse, I. Ellis, C. Elston, 2004, Virchows Archiv.

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

R. Langer, S. Rauser, H. Höfler, 2011, BMC Cancer.

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts

M. Beckmann, P. Fasching, T. Fehm, 2015, Breast Care.

Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

P. Lønning, T. Decker, A. Leo, 2017 .

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

P. Fasching, T. Fehm, A. Schneeweiss, 2015, Geburtshilfe und Frauenheilkunde.

Sentinel lymph node biopsy in staging small (up to 15 mm) breast carcinomas. Results from a European multi-institutional study

J. Peterse, A. Sapino, S. Bianchi, 2007, Pathology & Oncology Research.

13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)

M. Beckmann, T. Fehm, A. Schneeweiss, 2013, Breast Care.

Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany

M. Lux, N. Harbeck, T. Decker, 2021 .

Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany

M. Lux, N. Harbeck, T. Decker, 2021, Breast Care.

Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors

T. Decker, K. Geiger, T. Dechow, 2022, Oncology Research and Treatment.

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.

W. Scheithauer, M. Stauch, V. Heinemann, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2011, British Journal of Cancer.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

W. Scheithauer, V. Heinemann, J. Holch, 2017, European journal of cancer.

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

W. Scheithauer, V. Heinemann, J. Holch, 2017, Oncotarget.

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

W. Scheithauer, M. Stauch, V. Heinemann, 2017, International journal of cancer.

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).

V. Heinemann, T. Decker, C. Denzlinger, 2020, European journal of cancer.

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper

M. Nöthen, H. Einsele, C. Bokemeyer, 2020, Oncology Research and Treatment.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE‐3 (AIO KRK‐0306)

W. Scheithauer, V. Heinemann, M. Lerch, 2021, International journal of cancer.

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2014, Journal of Cancer Research and Clinical Oncology.

Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3)

V. Heinemann, J. Holch, T. Decker, 2021, International journal of cancer.

Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

M. Stauch, V. Heinemann, T. Decker, 2020, Clinical Cancer Research.

Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer

F. Lordick, U. Martens, T. Decker, 2020, JAMA network open.

Interdisciplinary consensus on the use and technique of vacuum-assisted stereotactic breast biopsy.

W. Böcker, T. Decker, I. Schreer, 2003, European journal of radiology.

Impact of exact segment by segment primary tumor location status on anti-EGFR antibody first-line treatment efficacy in RAS/BRAF wild-type and BRAF mutant metastatic colorectal cancer. A pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

V. Heinemann, T. Decker, A. Tannapfel, 2021 .

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

W. Scheithauer, M. Stauch, V. Heinemann, 2016, The Lancet. Oncology.

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

P. Lønning, S. Johnston, T. Decker, 2018, The Lancet. Oncology.

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma

C. Porta, M. Highley, E. Tartour, 2021, Cells.

Origin and differentiation of breast nipple syringoma

T. Decker, D. Metze, I. Buchwalow, 2012, Scientific Reports.

Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry

I. Ellis, P. Tan, S. Fox, 2013, The American journal of surgical pathology.

Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

E. Morris, R. Kubik-Huch, T. Decker, 2018, Breast Cancer Research and Treatment.

Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients.

J. Peterse, A. Sapino, S. Bianchi, 2007, American journal of surgery.

Clinical surgery-International Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients

J. Peterse, A. Sapino, S. Bianchi, 2007 .

Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.

W. Scheithauer, M. Stauch, V. Heinemann, 2014 .

Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC)

M. Beckmann, P. Fasching, T. Fehm, 2013 .

A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance

Diethelm Wallwiener, D. Wallwiener, M. Untch, 2005, Cancer.

Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany

M. Untch, A. Lebeau, P. Sinn, 2019, Breast.

Papilläre Tumoren der Mamma

T. Decker, D. Hungermann, H. Bürger, 2006, Der Pathologe.

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

V. Heinemann, T. Decker, A. Tannapfel, 2022, Cancers.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).

V. Heinemann, T. Decker, C. Denzlinger, 2022, European journal of cancer.

Correction to: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

E. Morris, R. Kubik-Huch, T. Decker, 2019, Breast Cancer Research and Treatment.

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306

W. Scheithauer, V. Heinemann, J. Holch, 2022, European Radiology.

Stereotactic vacuum-assisted breast biopsies in 500 women with microcalcifications: radiological and pathological correlations.

T. Decker, Thomas Decker, Ute Kettritz, 2005, European journal of radiology.

Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer

K. Götze, T. Decker, C. Peschel, 2012, Journal of Cancer Research and Clinical Oncology.

St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods

Paul J. van Diest, P. Diest, T. Decker, 2016, Breast Cancer Research and Treatment.

[Standardized pathologic examination of breast excision specimen. Relevance within an interdisciplinary practice protocol for quality management of breast saving therapy].

T. Decker, M. Ruhnke, W. Schneider, 1997, Der Pathologe.

LBA11INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION

W. Scheithauer, V. Heinemann, T. Decker, 2014 .

O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306)

W. Scheithauer, M. Stauch, V. Heinemann, 2014 .

Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group

F. Lordick, G. Folprecht, T. Decker, 2007 .

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

W. Scheithauer, M. Stauch, V. Heinemann, 2022, British Journal of Cancer.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306.

W. Scheithauer, V. Heinemann, T. Decker, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.

W. Scheithauer, P. Wirapati, H. Lenz, 2017 .

Performance of 4 Immunohistochemical Phosphohistone H3 Antibodies for Marking Mitotic Figures in Breast Cancer

P. V. van Diest, P. V. van Diest, T. Decker, 2016, Applied immunohistochemistry & molecular morphology : AIMM.

Breast cancer prognostic classification in the molecular era: the role of histological grade

Shu Ichihara, Sunil Badve, Ian O Ellis, 2010, Breast Cancer Research.

Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective

A. Schneeweiss, H. Tesch, N. Harbeck, 2014, Breast Care.

Improving the reproducibility of diagnosing micrometastases and isolated tumor cells

S. Bianchi, M. Lacerda, T. Decker, 2005, Cancer.

Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience

T. Decker, R. Seifert, T. Dechow, 2021, Oncology Research and Treatment.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Hartmut Link, Michael Scholz, Thomas Kirchner, 2014, The Lancet. Oncology.

Breast carcinomas of low malignant potential

S. Schnitt, T. Decker, F. Fend, 2021, Virchows Archiv.

A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ)

T. Decker, M. Schostak, S. Schmitz, 2019, Urologia Internationalis.

Minimal invasive biopsy results of "uncertain malignant potential" in digital mammography screening: high prevalence but also high predictive value for malignancy.

W. Heindel, W. Böcker, T. Decker, 2011, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

The requirements of a specialist Breast Centre.

R. Mansel, F. Cardoso, A. Wilson, 2013, European journal of cancer.

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

C. Denkert, W. Eiermann, F. Marmé, 2015, Cancer.

Improving the reproducibility of diagnosing micrometastases and isolated tumor cells

S. Bianchi, M. Lacerda, T. Decker, 2005, Cancer.

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

H. Einsele, T. Brümmendorf, F. Bassermann, 2012 .

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients

T. Decker, T. Winder, K. Geiger, 2022, Frontiers in Oncology.

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

C. Denkert, N. Burchardi, V. Nekljudova, 2022, ESMO open.

[Ductal hyperplasia and ductal carcinoma in situ. Definition--classification--differential diagnosis].

W. Böcker, T. Decker, M. Ruhnke, 1997, Der Pathologe.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

M. Stauch, V. Heinemann, H. Hass, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Immunohistochemistry in breast pathology: differential diagnosis of epithelial breast lesions].

W. Böcker, T. Decker, D. Hungermann, 2009, Der Pathologe.

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.

W. Scheithauer, V. Heinemann, T. Decker, 2020, European journal of cancer.

Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast

A. Bankfalvi, T. Decker, F. Otterbach, 2000, Histopathology.

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

F. Lordick, T. Schuster, G. Folprecht, 2010, British Journal of Cancer.

Electron microscopy of liver in patients with chronic haemodialysis.

H. David, P. Reinke, T. Decker, 1991, Experimental pathology.

[The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis].

W. Böcker, T. Decker, D. Hungermann, 2006, Der Pathologe.

VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer

T. Decker, C. Lerchenmüller, A. Muendlein, 2019, Breast Cancer Research and Treatment.

W. Scheithauer, V. Heinemann, J. Holch, 2022, European Radiology.

Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways

C. Poremba, L. Riethdorf, T. Decker, 1999, The Journal of pathology.

Genome-wide expression profiling as a clinical tool

J. Reis-Filho, T. Decker, F. Geyer, 2009 .

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).

V. Heinemann, T. Decker, C. Denzlinger, 2021, European journal of cancer.

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

W. Scheithauer, P. Wirapati, V. Heinemann, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Overcoming resistance against ErbB inhibitory drugs by simultaneously targeting downstream effector kinases in breast cancer cells

T. Decker, 2010 .

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, W. Scheithauer, M. Stauch, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Basal carcinoma of the breast revisited: an old entity with new interpretations

S. Jeffrey, T. Decker, W. Boecker, 2008, Journal of Clinical Pathology.

[Genome-wide expression profiling as a clinical tool: are we there yet?].

J. Reis-Filho, T. Decker, F. Geyer, 2009, Der Pathologe.

Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO

T. Decker, H. Lehmann, J. Uhlig, 2021, Oncology Research and Treatment.

Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer

A. Haid, T. Decker, B. Rohde, 2015, Journal of Cancer Research and Clinical Oncology.

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

T. Wilson, A. Bardia, T. Decker, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.

P. Fasching, T. Fehm, A. Schneeweiss, 2021, European journal of cancer.

Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.

P. Regitnig, A. Sapino, J. Wesseling, 2014, Breast.

Sentinel lymph node biopsy and non-sentinel node involvement in special type breast carcinomas with a good prognosis.

J. Peterse, A. Sapino, S. Bianchi, 2007, European journal of cancer.

Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry.

P. Sorensen, Meenakshi Singh, K. Schaefer, 2003, Human pathology.

The Future Role of PET Imaging in Metastatic Breast Cancer

T. Decker, K. Herrmann, R. Seifert, 2021, Oncology Research and Treatment.

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

W. Scheithauer, V. Heinemann, T. Decker, 2020, British Journal of Cancer.

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

T. Decker, P. Klare, A. Hahn, 2020, BMC Cancer.

Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling‐based or mitotic activity index‐based proliferation assessment

T. Decker, C. Focke, K. Finsterbusch, 2019, Histopathology.

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study

P. V. van Diest, A. Sapino, J. Wesseling, 2014, Breast Cancer Research and Treatment.

Invasion in breast lesions: the role of the epithelial–stroma barrier

Kylie L. Gorringe, I. Ellis, P. Tan, 2018, Histopathology.

Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours

P. Diest, T. Decker, Cornelia M Focke, 2016, Histopathology.

Interlaboratory variability of Ki67 staining in breast cancer.

Eberhard Korsching, P. V. van Diest, T. Decker, 2017, European Journal of Cancer.

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis

I. Ellis, P. V. van Diest, E. Rakha, 2021, Cancers.

Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume

P. Diest, T. Decker, C. Focke, 2017, Annals of Surgical Oncology.

[Prognostic and predictive factors of invasive breast cancer: update 2009].

W. Böcker, T. Decker, D. Hungermann, 2009, Der Pathologe.

Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines.

J. Peterse, I. Ellis, C. Elston, 2003, European journal of cancer.

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).

W. Scheithauer, V. Heinemann, J. Holch, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients

W. Jagla, A. Gaumann, T. Decker, 2021, Scientific Reports.

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

M. Hallek, S. Stilgenbauer, T. Decker, 2022, Leukemia & lymphoma.

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

M. Hallek, S. Stilgenbauer, T. Decker, 2022, HemaSphere.

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046

T. Fehm, N. Harbeck, Marcus Schmidt, 2021, Senologie - Zeitschrift für Mammadiagnostik und -therapie.

Duktale Hyperplasie und Duktales Carcinoma in situ Definition – Klassifikation – Differentialdiagnose

W. Böcker, T. Decker, M. Ruhnke, 1997, Der Pathologe.

[Sentinel node biopsy in breast cancer: pathological analysis and interpretation].

T. Decker, G. Cserni, T. Decker, 2009, Der Pathologe.

Discriminating between micrometastases and isolated tumor cells in a regional and institutional setting.

A. Sapino, T. Decker, G. Cserni, 2006, Breast.

Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology

J. Peterse, I. Ellis, C. Elston, 2004, Journal of Clinical Pathology.

Sentinel Node Biopsy in Breast Cancer

K. Winzer, H. Schirrmeister, T. Kühn, 2000, Oncology Research and Treatment.

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

M. Vogel, T. Decker, W. Berdel, 2014 .

Abstract P4-13-06: Results of the 3rd interim analysis of the non-interventional trial BRAWO – Subanalysis of patients <70 years and ≥ 70 years

P. Fasching, A. Schneeweiss, H. Tesch, 2016 .

Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO.

P. Fasching, F. Schuetz, H. Tesch, 2014 .

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial

M. Lux, P. Fasching, A. Schneeweiss, 2018, International journal of cancer.

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

W. Scheithauer, M. Stauch, V. Heinemann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer

T. Decker, T. Winder, C. Marth, 2013, Journal of Cancer Research and Clinical Oncology.

Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization – design and objectives of the Diagnosis Optimisation Study (DIOS)

S. Hauptmann, A. Stang, A. Heinig, 2007, BMC Cancer.

Nintedanib plus mFOLFOX6 as second‐line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo‐controlled, phase II TRICC‐C study (AIO‐KRK‐0111)

V. Heinemann, T. Seufferlein, T. Decker, 2020, International journal of cancer.

The reliability of histological grade in breast cancer core needle biopsies depends on biopsy size: a comparative study with subsequent surgical excisions

P. Diest, T. Decker, C. Focke, 2016, Histopathology.

First Epidemiological Analysis of Breast Cancer Incidence and Tumor Characteristics after Implementation of Population-Based Digital Mammography Screening

H. Hense, W. Heindel, T. Decker, 2010 .

Calcifications in digital mammographic screening: improvement of early detection of invasive breast cancers?

W. Heindel, W. Böcker, T. Decker, 2010, Radiology.

First epidemiological analysis of breast cancer incidence and tumor characteristics after implementation of population-based digital mammography screening.

H. Hense, W. Heindel, T. Decker, 2009, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

First Epidemiological Analysis of Breast Cancer Incidence and Tumor Characteristics after Implementation of Population-Based Digital Mammo- graphy Screening Erste epidemiologische Analyse der Brustkrebsinzidenz und der Tumorcharakteristika nach Implementierung des populationsbezogenen digitalen Mamm

H. Hense, W. Heindel, T. Decker, 2009 .

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers

C. Quinn, P. Regitnig, A. Sapino, 2016, Virchows Archiv.

Stereotactic vacuum-assisted breast biopsies in 500 women with microcalcifications: radiological and pathological correlations

T. Decker, Thomas Decker, U. Kettritz, 2006 .

Breast Density and Breast Cancer Screening with Digital Breast Tomosynthesis: A TOSYMA Trial Subanalysis.

H. Hense, W. Heindel, J. Gerss, 2022, Radiology.

Mikrokalkdiagnostik an minimal-invasiven Biopsien im Mammographie-Screening

W. Heindel, W. Böcker, T. Decker, 2009, Der Pathologe.

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

T. Decker, T. Trarbach, M. Indorf, 2017, BMC Cancer.

[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors

M. Heuschmid, K. Herrmann, T. Decker, 2021, Oncology Research and Treatment.

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry

T. Fehm, C. Denkert, V. Nekljudova, 2022, ESMO open.

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).

V. Heinemann, T. Decker, C. Denzlinger, 2021, European journal of cancer.

Sturge-Weber syndrome with posterior fossa involvement.

P. Barnes, T. Decker, K. Jones, 1994, AJNR. American journal of neuroradiology.

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

V. Heinemann, T. Decker, C. Denzlinger, 2022, Frontiers in Oncology.

Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259].

W. Scheithauer, V. Heinemann, T. Decker, 2022, European journal of cancer.

Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL

N. Harbeck, E. Stickeler, T. Decker, 2023, Breast Cancer Research and Treatment.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

W. Scheithauer, M. Stauch, V. Heinemann, 2017, European journal of cancer.

Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer

T. Decker, T. Dechow, A. Leiherer, 2023, Oncology Research and Treatment.

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

A. Bardia, T. Decker, G. Bertelli, 2021, Journal of Clinical Oncology.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.

W. Scheithauer, V. Heinemann, T. Decker, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based tr

P. Lønning, T. Decker, A. Leo, 2015 .

Abstract 2615: Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study

J. Hasenauer, F. Lordick, B. Rau, 2018, Clinical Research (Excluding Clinical Trials).

Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial

W. Scheithauer, V. Heinemann, J. Holch, 2018, International journal of cancer.

Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.

T. Decker, S. Hegewisch‐Becker, C. Steffens, 2011, Journal of Clinical Oncology.

Calcifi cations in Digital Mammographic Screening : Improvement of Early Detection of Invasive Breast Cancers ? 1

W. Heindel, W. Böcker, T. Decker, 2010 .

Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)

M. Lux, P. Fasching, A. Schneeweiss, 2015 .

LBA9BREAST CANCER TREATMENT WITH EVEROLIMUS AND EXEMESTANE FOR ER+ WOMEN - RESULTS OF THE 2ND INTERIM ANALYSIS OF THE NON-INTERVENTIONAL TRIAL BRAWO

P. Fasching, A. Schneeweiss, H. Tesch, 2014 .

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

T. Decker, T. Trarbach, M. Indorf, 2017, BMC Cancer.

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

M. Lux, P. Fasching, A. Schneeweiss, 2018, Journal of bone oncology.

[MALT Lymphoma of the Conjunctiva in a 13-year old Child--5-Year Relapse-free Follow-up Following Antibiotic Treatment].

T. Decker, H. Höh, S. Armbrust, 2016, Klinische Monatsblatter fur Augenheilkunde.

Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients

T. Decker, T. Winder, K. Geiger, 2023, Journal of Cancer Research and Clinical Oncology.

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial

T. Decker, R. Depenbusch, S. Hegewisch‐Becker, 2016, Breast Cancer Research and Treatment.

Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

P. V. van Diest, M. Gnant, R. Mann, 2023, Virchows Archiv.

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, Volker Heinemann, W. Scheithauer, 2013 .

Digital mammography screening: average glandular dose and first performance parameters.

W. Heindel, S. Spital, T. Decker, 2007, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO

P. Fasching, A. Schneeweiss, F. Schuetz, 2019, Poster Session Abstracts.

Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.

P. Fasching, F. Schuetz, H. Tesch, 2017 .

Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).

R. Greil, A. Ganser, A. Hinke, 2018 .

Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

Pathology of hepatic peroxisomes in chronic hepatitis B and immunosuppression.

H. David, P. Reinke, T. Decker, 1988, Experimental pathology.

Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.

T. Decker, T. Winder, C. Marth, 2014, European journal of cancer.

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

W. Scheithauer, M. Stauch, V. Heinemann, 2015 .

Personalisierte Medizin – von der Translation zur Klinik

S. Loibl, T. Decker, Marcus Schmidt, 2023, Die Gynäkologie.

Basal carcinoma of the breast revisited: an old entity with new interpretations

S. Jeffrey, T. Decker, W. Boecker, 2008, Journal of Clinical Pathology.

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

[Sentinel node biopsy in breast carcinoma. Interdisciplinary agreement consensus of the German Society for Serology for quality controlled application in routine clinical testing].

K. Winzer, H. Schirrmeister, T. Kühn, 2004, Der Pathologe.

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple

H. Einsele, T. Brümmendorf, F. Bassermann, 2022, Blood.

Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in Germany

T. Decker, F. Hartmann, M. Welslau, 2023, International journal of cancer.

324P What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL

N. Harbeck, E. Stickeler, T. Decker, 2020 .

Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.

V. Heinemann, T. Decker, G. Schuch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD18-07: Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial

A. Schneeweiss, D. Wallwiener, K. Pantel, 2023, Cancer Research.

T. Decker, P. Klare, A. Hahn, 2020, BMC Cancer.

RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis.

P. Fasching, T. Fehm, A. Schneeweiss, 2018 .

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

M. Beckmann, T. Fehm, A. Schneeweiss, 2013, Breast care.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

W. Scheithauer, V. Heinemann, J. Holch, 2019, European journal of cancer.

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).

W. Scheithauer, M. Stauch, V. Heinemann, 2017 .

New Opportunities in Advanced Breast Cancer

T. Decker, M. Schmidt, 2021, Oncology Research and Treatment.

Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC)

M. Beckmann, P. Fasching, T. Fehm, 2013 .

Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management

I. Ellis, P. Tan, S. Fox, 2016, Histopathology.